மதிப்பீட்டாளர் யாரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மதிப்பீட்டாளர் யாரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மதிப்பீட்டாளர் யாரி Today - Breaking & Trending Today

Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine


Share this article
Share this article
NEW YORK, May 25, 2021 /PRNewswire/  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.
Dear Shareholders,
I m excited to share with you significant milestones we have achieved over the past few months. Our oral delivery platform technology could apply to a range of proteins and disease modalities, and we expect over time to have a range of programs. We are currently advancing our two primary programs: oral insulin for diabetes and an oral COVID vaccine. We believe these milestones create an inflection point in the value for our company. ....

United States , Nadav Kidron , Estee Yaari , Oramed Pharmaceuticals Inc , Company Contact , Drug Administration , Oramed Pharmaceuticals , Exchange Commission , Oravax Medical Inc , Chief Executive Officer Nadav , First Oral Insulin Capsule , Biologics License Approval , Oravax Medical , Clinical Trial , Bring Value , Oramed Shareholders , Potentially Through Dividend Shares , Oravax Medical Shares , Medical Inc , Premas Biotech , Protein Oral Delivery , Investigational New Drug , ஒன்றுபட்டது மாநிலங்களில் , நாடவ் கீதிரோன் , மதிப்பீட்டாளர் யாரி , நிறுவனம் தொடர்பு ,

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma


Share:
NEW YORK, April 21, 2021 /PRNewswire/  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021  at 11:00 Eastern. 
 
 
Mr. Kidron, along with Premas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu, will discuss Oramed Pharmaceuticals oral insulin drug, currently in Phase 3 clinical trials, and the oral COVID-19 vaccine candidate of Oravax Medical Inc., which is 63% owned by Oramed Pharmaceuticals. Pre-clinical trials have shown that Oravax s oral vaccine candidate produces antibodies after a single dose and may potentially be a better ....

United States , Nadav Kidron , Prabuddha Kundu , James Molloy , Estee Yaari , Oramed Pharmaceuticals Inc , Company Contact , Drug Administration , Oramed Pharmaceuticals , Exchange Commission , Equity Research , Specialty Pharmaceuticals At Alliance Global Partners On , Oravax Medical Inc , Premas Biotech Co , Grand Rounds , Specialty Pharma , Managing Director , Specialty Pharmaceuticals , Alliance Global Partners , Premas Biotech Co Founder , Oramed Pharmaceutical , Protein Oral Delivery , Investigational New Drug , ஒன்றுபட்டது மாநிலங்களில் , நாடவ் கீதிரோன் , பிரபுட்ட குண்டு ,